MRSA Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Retapamulin as a Topical Decolonizing Agent for Mupirocin Resistant Methicillin Resistant Staphylococcus Aureus (MRSA)
Verified date | March 2020 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the efficacy of retapamulin to reduce carriage of MRSA via a randomized, double-blind, placebo-controlled clinical study testing retapamulin among patients with confirmed mupirocin-resistant nasal and/or rectal MRSA colonization. The sample size will include 27 subjects in each of the two arms of the study (retapamulin versus placebo) for a total of 54 subjects. Participants who are found to be nasal and/or rectal colonized with MRSA will be randomized to receive either retapamulin or placebo applied nasally and rectally for a total of 5 days. Nasal and rectal swabs will be collected at pre-defined time points during study duration (screening swab, swab one week after completion of topical therapy, swab 4 weeks after completion of topical therapy) to assess MRSA colonization status. The colonization rates of both groups will be assessed via Fisher's Exact Test.
Status | Completed |
Enrollment | 47 |
Est. completion date | March 18, 2019 |
Est. primary completion date | February 13, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 9 Months to 17 Years |
Eligibility |
Inclusion Criteria: 1. Admission to the general pediatric floor and pediatric intensive care units at NYU Langone Medical Center or visit to study team members at ODA clinic (Park Ave locations) in Williamsburg Brooklyn. 2. Ages 9 months to 17 years 3. Residing in the zip codes which reflect Orthodox Jewish neighborhoods where there is a current outbreak of this strain of MRSA. 4. Nasal and/or rectal culture positive for mupirocin-resistant methicillin-resistant Staphylococcus aureus (MRSA) Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Pregnant or lactating 2. Unable to appropriately consent 3. Open sores in either of the study sites (nares or rectum) 4. Recent surgical procedure to either study site (nares or rectum) 5. Concurrent use of Rifampin or Trimethoprim/Sulfamethoxazole 6. Current active MRSA infection 7. Immunocompromised 8. Presence of endotracheal tube, tracheostomy tube or other foreign body in upper airway |
Country | Name | City | State |
---|---|---|---|
United States | New York University School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With MRSA Carriage at 1 Week Post Decolonization With Retapamulin or Placebo | Study visit for nasal/peri-rectal swabs | 1 Week | |
Primary | Number of Partcipants With MRSA Carriage at 4 Weeks Post Decolonization With Retapamulin or Placebo | Study visit for nasal/peri-rectal swabs | 4 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181932 -
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
|
Phase 3 | |
Completed |
NCT03268122 -
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
|
N/A | |
Completed |
NCT04312776 -
Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS
|
||
Recruiting |
NCT04104178 -
Optimal Treatment of MRSA Throat Carriers
|
Phase 3 | |
Recruiting |
NCT04793152 -
Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
|
N/A | |
Completed |
NCT03601741 -
Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
|
N/A | |
Completed |
NCT02690415 -
Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
|
||
Enrolling by invitation |
NCT04297592 -
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
|
Phase 4 | |
Recruiting |
NCT05268120 -
MRSA Decolonization in Complicated Carriage
|
N/A | |
Completed |
NCT01167452 -
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
|
Phase 4 | |
Recruiting |
NCT04083092 -
Surveillance of Community-Associated MRSA
|
||
Recruiting |
NCT02443064 -
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
|
Phase 4 | |
Completed |
NCT02029872 -
Stop Community MRSA Colonization Among Patients
|
Phase 4 | |
Not yet recruiting |
NCT05696132 -
Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients
|
Phase 2 | |
Recruiting |
NCT02127658 -
MRSA Eradication and Decolonization in Children
|
N/A | |
Completed |
NCT00822276 -
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
|
N/A | |
Withdrawn |
NCT02547116 -
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
|
Phase 4 | |
Completed |
NCT01318213 -
Benefits of Universal Glove and Gowning
|
||
Enrolling by invitation |
NCT05395520 -
Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?
|